secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lineage Cell Therapeutics, Inc. (LCTX)
CIK:        0000876343
Form:       8-K
Filed at:   2026-08-06T20:11:42+00:00
Accession:  0001193125-26-338020
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lineage Cell Therapeutics Q2 2026 net income $1.5M; cash runway to Q3 2028
--------------------------------------------------------------------------

- Q2 2026 net income of $1.5M ($0.01 basic EPS) vs net loss of $30.5M in Q2 2025; revenue $1.1M, down from $2.8M.
- Cash $50.8M expected to fund operations into Q3 2028.
- RG6501 (OpRegen) Phase 1/2a 3-year data showed sustained BCVA gains and retinal structure restoration in Cohort 4.
- COR1 corneal endothelial cell therapy program advanced to in-vivo animal testing; initial data expected in 2026.
- Established Scientific Advisory Board with Joachim Fruebis, PhD as founding member.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/876343/000119312526338020/0001193125-26-338020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/876343/000119312526338020/lctx-20260806.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-338020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer